Loading…
Amneal Pharmaceuticals, Inc. is projected to rise to $15.36 by 2027, a +20% move from its current price of $12.78. AMRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.57 | $12.79 | $13.01 | +0.04% |
| May 30 | $12.48 | $12.79 | $13.11 | +0.08% |
| May 31 | $12.42 | $12.80 | $13.18 | +0.12% |
| Jun 1 | $12.37 | $12.80 | $13.25 | +0.16% |
| Jun 2 | $12.32 | $12.81 | $13.31 | +0.20% |
| Jun 3 | $12.28 | $12.81 | $13.36 | +0.24% |
| Jun 4 | $12.24 | $12.82 | $13.41 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.24 | $12.82 | $13.41 | +0.28% |
| Week 2 | $12.05 | $12.85 | $13.71 | +0.55% |
| Week 3 | $11.91 | $12.89 | $13.95 | +0.83% |
| Week 4 | $11.79 | $12.92 | $14.16 | +1.11% |
| Week 5 | $11.70 | $12.96 | $14.35 | +1.39% |
| Week 6 | $11.62 | $12.99 | $14.53 | +1.67% |
| Week 7 | $11.55 | $13.03 | $14.70 | +1.95% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease.
This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Amneal Pharmaceuticals, Inc. (AMRX) is a global biopharmaceutical company with a current price of $12.42 and a market capitalization of $3.96B. It holds the rank of 1514 in market size.
Near-term prospects are shaped by a forecast that shows a rising trajectory in average prices over the coming years, with notable milestones at 2030 and beyond. The forecast lists a 2026 average of $12.42 and projects growth to a 2030 average of $22.90, a 2040 average of $51.12, and a 2050 average of $110.68, with corresponding ROI figures of 84.4%, 311.6%, and 791.1% for those distant milestones. The overall tone across years 2027–2050 is bullish.
A major floor 16.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 8.8% above — a clean break opens room to run.
A major ceiling 18.9% above — clearing it would confirm fresh momentum.
Key AMRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.53 | Buy | $12.57 | Buy |
| MA 10 | $12.29 | Buy | $12.51 | Buy |
| MA 20 | $12.69 | Buy | $12.59 | Buy |
| MA 50 | $12.62 | Buy | $12.74 | Buy |
| MA 100 | $13.16 | Sell | $12.66 | Buy |
| MA 200 | $11.97 | Buy | $11.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.79 | Neutral |
| Stoch RSI (14) | 62.32 | Neutral |
| CCI (20) | 13.53 | Neutral |
| Williams %R (14) | -49.21 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.18 | Sell |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 50.79 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 67.53 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 12.80 | Sell |
| ADX (14) | 14.06 | Neutral |
| ATR (14) | 0.20 | Info |
Technical picture for the next 30 days shows a bullish tilt. RSI14 is 50, with the 50-day simple moving average at $12.58 and the 200-day simple moving average at $11.93, indicating the price is hovering near the short to intermediate-term moving averages.
The stock has a support level at $11.81 and a resistance level at $13.91. The 30-day price range runs from a low of $11.08 to a high of $13.93, signaling moderate volatility within a defined band. Overall, the near-term setup favors upside if resistance is broken, while a failure to hold support could constrain upside.” ,
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.81 | $12.78 | $16.65 | 0% | Neutral | |
| $12.55 | $15.36 | $19.69 | +20% | Bullish | |
| $13.50 | $16.83 | $22.13 | +32% | Bullish | |
| $14.73 | $18.63 | $25.01 | +46% | Bullish | |
| $18.61 | $23.86 | $32.60 | +87% | Bullish | |
| $20.38 | $26.44 | $36.68 | +107% | Bullish | |
| $21.69 | $28.46 | $40.03 | +123% | Bullish | |
| $24.16 | $32.03 | $45.63 | +151% | Bullish | |
| $24.12 | $32.30 | $46.56 | +153% | Bullish | |
| $25.66 | $34.69 | $50.56 | +171% | Bullish | |
| $38.61 | $54.42 | $83.09 | +326% | Bullish | |
| $77.97 | $117.85 | $192.83 | +822% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $11.81 | $12.78 | $14.96 | +0.00% |
| June 2026 | $11.22 | $13.09 | $15.57 | +2.44% |
| July 2026 | $11.29 | $13.25 | $15.90 | +1.20% |
| August 2026 | $11.13 | $13.12 | $15.87 | -0.94% |
| September 2026 | $11.27 | $13.33 | $16.22 | +1.61% |
| October 2026 | $11.56 | $13.73 | $16.79 | +2.94% |
| November 2026 | $11.47 | $13.66 | $16.78 | -0.51% |
| December 2026 | $11.30 | $13.49 | $16.65 | -1.21% |
Click any year to see its month-by-month AMRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Amneal Pharmaceuticals, Inc.'s 2026 outlook centres on $12.78, within a $11.81 to $16.65 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AMRX could reach as high as $19.69, with a base case around $15.36 and support toward $12.55 — roughly +20% from $12.78. Momentum favours further upside here.
Expect AMRX to range from $13.50 to $22.13 through 2028. The $16.83 average target implies a +32% move from current prices. That is up +10% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AMRX price prediction for 2029 points to an average of $18.63 (low $14.73, high $25.01) — a potential gain of +46% on today's $12.78. Momentum favours further upside here.
In 2030, AMRX is projected to trade between $18.61 and $32.60, averaging $23.86 — a potential gain of +87% from today's $12.78. That is up +28% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Amneal Pharmaceuticals, Inc.'s 2031 outlook centres on $26.44, within a $20.38 to $36.68 range. That is up +11% on the projected 2030 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2032, AMRX could reach as high as $40.03, with a base case around $28.46 and support toward $21.69 — roughly +123% from $12.78. Buyers look set to stay in control over this stretch.
Expect AMRX to range from $24.16 to $45.63 through 2033. The $32.03 average target implies a +151% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The AMRX price prediction for 2034 points to an average of $32.30 (low $24.12, high $46.56) — a potential gain of +153% on today's $12.78. Buyers look set to stay in control over this stretch.
In 2035, AMRX is projected to trade between $25.66 and $50.56, averaging $34.69 — a potential gain of +171% from today's $12.78. That is up +7% on the projected 2034 average. Momentum favours further upside here.
Amneal Pharmaceuticals, Inc.'s 2040 outlook centres on $54.42, within a $38.61 to $83.09 range. That is up +57% on the projected 2035 average. That marks a +326% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AMRX could reach as high as $192.83, with a base case around $117.85 and support toward $77.97 — roughly +822% from $12.78. Momentum favours further upside here.
Investing $1,000 in AMRX today (≈ 78.247261 AMRX) could be worth
$9,221.21
+$8,221.21 (+822%) by 2050 · US Dollar
Based on the average projected AMRX price of $117.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMRXwould be worth at today's price.
$1,000 invested in AMRX on May 27, 2025 (≈ 137.174212 AMRX) would be worth
$1,753.09
+$753.09 (+75.3%) today · 1.75× · US Dollar
Based on a AMRX entry price of $7.29 vs. today's $12.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.23 | $1,044.97 | +4.5% |
| 1 month ago | $12.57 | $1,016.71 | +1.7% |
| 3 months ago | $14.49 | $881.99 | -11.8% |
| 6 months ago | $12.52 | $1,020.77 | +2.1% |
| 1 year ago | $7.29 | $1,753.09 | +75.3% |
| All time (5.0y) ago | $5.69 | $2,246.05 | +124.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMRX forecast.
Our base-case forecast reaches $26.00 around 2031.
Implied market cap at $26.00: $8.29B
From a multi-year perspective, the forecast paints a clear bullish progression with steadily rising averages. The 2026 average is $12.42, followed by a 2027 average of $14.89, 2028 of $16.20, and 2029 of $17.93, culminating in a 2030 average of $22.90 and a 2031 average of $25.20. The trajectory continues through 2032 at $27.20, 2033 at $30.60, 2034 at $30.53, and 2035 at $32.91.
The long-horizon milestones highlight a path to $51.12 on average by 2040 and to $110.68 on average by 2050, with ROI projections of 311.6% in 2040 and 791.1% in 2050. Specifically, the 2040 forecast shows an average of $51.12 with a 311.6% ROI, and the 2050 forecast shows an average of $110.68 with a 791.1% ROI. While these figures point to a strong upward trajectory, they are estimates and not guarantees, and actual results may vary due to market, regulatory, and company-specific factors.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $22.90 with a min of $17.86 and a max of $31.29 and an ROI of 84.4%.
The forecast shows a bullish path beyond 2026, with rising averages: 2027 $14.89 (ROI 19.9%), 2028 $16.20 (ROI 30.4%), 2029 $17.93 (ROI 44.4%), 2030 $22.90 (ROI 84.4%), 2040 $51.12 (ROI 311.6%), and 2050 $110.68 (ROI 791.1%). These are estimates, not guarantees.
Yes. The forecast for 2040 shows an average of $51.12 with a max of $78.06, indicating a bullish long-term path toward that level.
The near-term setup is bullish with a current price of $12.42, RSI 50, SMA50 at $12.58, SMA200 at $11.93, support at $11.81, and resistance at $13.91. The 30-day range sits between $11.08 and $13.93.
Current price is $12.42. Market capitalization is $3.96B, and the rank is 1514.
Amneal Pharmaceuticals, Inc. Community Discussion
0Share your Amneal Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.